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CC BY-NC-ND license (http://creativeAbstract Lipoprotein-associated phospholipase A2 (Lp-PLA2), a member of the phospholipase
A2 superfamily, is an enzyme that hydrolyses phospholipids, is found in blood circulation as a sign
of inflammation, and takes a role in atherogenesis. There is an epidemiologic relation between
increased Lp-PLA2 levels and coronary heart disease. Lp-PLA2 is an enzyme that is produced by
macrophages and takes a role as an independent predictor of a coronary event. A genetic variant
of Val279Phe on the Lp-PLA2 gene has been reported with various results in Japan, China, Korea,
and Caucasian populations. This study aims to analyse the influence of the Val279Phe genetic
variant on acute myocardial infarction (AMI) at Saiful Anwar Hospital, Indonesia. This study
was conducted on 151 patients (111 AMI patients and 40 non-AMI patients). The genetic variant
of Val279Phe was identified through a genotyping method. There were no significant differences
in age, total cholesterol level, LDL-C (low-density lipoprotein cholesterol) level, and family his-
tory data between AMI and non-AMI patients. However, AMI patients had low HDL-C (high-den-
sity lipoprotein cholesterol), triglyceride levels, dyslipidaemia, and hypertension risk factors
compared to non-AMI patients. The frequency of the GG genotype (279Val) was dominant in
both AMI and non-AMI groups. Further analysis suggested that the GG genotype has a 2.9 times
greater risk of AMI compared to the GT/TT genotype (279Phe). This study concluded that theartment, Faculty of Mathematics and Natural Sciences, Brawijaya University, Malang, Indonesia.
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opment of early detection and improving strategy to prevent AMI in patients.
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Cardiovascular disease causes 30% of deaths in the world.1
One cardiovascular disease is coronary heart disease (CHD),
that caused one in six death cases in America in 2008.2
About half a million people in China have had myocardial
infarction, and 2 million people have suffered from a
stroke.1 A survey of the Indonesia Health Department in
2007 showed that CHD was in third position as a cause of
death disease after stroke and hypertension.3
Atherosclerosis is a chronic, progressive, and fundamental
process that causes CHD.1,4e9 The expression of lipoprotein-
associated phospholipase A2 (Lp-PLA2) triggers atheroscle-
rosis. Therefore, Lp-PLA2 is used as a biomarker for cardio-
vascular events in the future. This enzyme is produced by
monocytes as an effect of inflammation mediator stimula-
tion. In blood circulation, 80% of Lp-PLA2 binds with low-
density lipoprotein (LDL) and 15e20% of it binds with high-
density lipoprotein (HDL).5,6,10,11 Lp-PLA2 is also known as
platelet-activating factor acetylhydrolase (PAF-AH) because
it hydrolyses platelet-activating factor (PAF).5e7,10 PAF is a
substrate that correlates with thrombogenesis and increases
the risk of a coronary event. Lp-PLA2 catalyses the degrada-
tion of PAF to the biologically inactive products LYSO-PAF and
acetate. On the other hand, the enzyme hydrolyses oxidized
polyunsaturated fatty acids, producing lysophosphatidylcho-
line (lysoPC) that upregulates inflammatorymediators, which
have potential to be disruptive.4e8,10,12
Substitution of guanine (G) for thymine (T) in exon 9 at
position 994 leads to the alteration of amino acid synthesis
from valine into phenylalanine on residue 279 (Val279Phe) of
Lp-PLA2. The 279Phe variant increases the risk of vascular
disease and stroke.10 Moreover, Han’s study indicated that
the 279Phe allele was more often found in coronary artery
disease (CAD) patients (13.5%) than in healthy controls
(9.3%; p Z 0.024) in a Chinese population. The severity of
atherosclerosis was greater in Val279Phe carriers.13 This
condition was different from observation data in the Korean
population which showed that the heterozygous mutation
has a lower risk of cardiovascular disease. Enzyme activity of
the heterozygous mutation was 23% lower than the homo-
zygous (V/V) mutation in non-acute myocardial infarction
(AMI) patients.10,13e18 The aim was to investigate the influ-
ence of the Val279Phe genetic variant in men with AMI at
Saiful Anwar Hospital, Malang, Indonesia.
Methods
Sample collection
This study was an observational case-control design. Samples
were taken consecutively from 151 Indonesian men with agerange 30e80 years in Saiful Anwar Hospital, Malang,
Indonesia. Patients were divided into two groups, i.e. AMI and
non-AMI groups. The AMI group consisted of 111 patients who
were diagnosed as AMI patients with or without revasculari-
zation using thrombolytics. Levels of cardiac enzymes such as
CPK, CKMB, and troponin I were measured and showed an
increase in the first 6 h after AMI onset that was higher than
normal. Electrocardiogram results showed ST segment devi-
ation in both elevation and depression of anterior, ante-
roseptal, extensive anterior, inferior, right ventricular,
posterior, and new left bundle branch block (LBBB) patterns.
Patients were taken care of in the Cardiovascular Care Unit
(CVCU), Dr. Saiful Anwar Hospital. The non-AMI group con-
sisted of 40 patients who came to the outpatient cardiology
clinic with AMI risk factors without ischaemic symptoms and
ECG abnormality. The non-AMI group had traditional risk
factors such as smoking, hypertension, dyslipidaemia, and
normal treadmill test results. Stratification of risk factors was
done to predict cardiovascular events for the next ten years,
which grouped patients based on Framingham risk stratifica-
tion score into low risk, moderate risk, and high risk. Patients
who were diagnosed with diabetes mellitus, had had statin
therapy for 12 days, had vascular disease (e.g. peripheral
artery disease, PAD), infection,malignancy, orwereunable to
perform the treadmill test were excluded from the study. This
study has followed the Code of Ethics of the world Medical
Association (Declaration of Helsinki) for experiments in
humans and approved by Brawijaya University- Dr. Saiful
Anwar Hospital Ethics Committee.
PCR-RFLP
Genotyping was done by using the PCR-RFLP method ac-
cording to a previous report.19 A peripheral blood sample
was put into a vacutainer with EDTA. DNA isolation was
done using a Qiagen QIAmp Whole DNA Isolation Mini Kit
corresponding to the manufacturer’s instructions. Isolated
DNA was amplified using polymerase chain reaction (PCR)
with forward primer 50CCCCATGAAATGAACAATTATAT and
reverse 50GGGGGCAAAAGAATAGCCTTATAA at an annealing
temperature of 53 C. RFLP was performed using the PCR
product with restriction enzyme BST4Ci that recognizes
AC‘N’GT. The cutting temperature used for RFLP was 65 C.
The size of PCR-RFLP products was 148 bp and 169 bp for
the G allele, and 317 bp for the T allele. Then, the samples
were analysed by a sequencing method.
Statistical analysis
Data were presented asmean SD. The differences between
two sample groups and controls were tested using t-test
(normal numeric distribution data) and ManneWhitney test
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between the AMI and non-AMI groups were analysed to
calculate the odds ratio (OR) between GG, GT, and TT. Sta-
tistical analysis was done using SPSS version 17 (SPSS Inc).
Results
Patients in the non-AMI group performed the treadmill test
with normal results. Based on Framingham risk score ATP
III, non-AMI patients were divided into three criteria: 11
(27.5%) patients had low-risk criteria, 14 (35%) patients
moderate-risk criteria, and 15 (37.5%) patients had high-
risk criteria. The HDL-C levels of AMI patients were signifi-
cantly lower than those of non-AMI patients (38.86  11.29
vs. 44.23  10.82; pZ 0.010). The BMI of non-AMI patients
was significantly higher than AMI patients (25.7  3.22 vs.
23.42  3.41; p Z 0.000). Triglyceride levels were signifi-
cantly higher in non-AMI patients than AMI patients
(174.6  148.82 vs. 124.78  68.11; pZ 0.009). There were
no significant differences between AMI and non-AMI pa-
tients for age, total cholesterol, and LDL cholesterol levels
(Table 1). Genotype frequencies (GG, GT, and TT) in AMI
and non-AMI patients did not differ. Both the AMI and non-
AMI groups had higher GG genotype frequency than GT or
TT (Table 2; Fig. 1). The difference frequency was a known
influence on OR in the AMI group; it was 2.9 times higher
than in the non-AMI group (Table 3).
Discussion
Non-AMI patients had higher BMI and triglyceride levels
than AMI patients. This may be caused by non-AMI patientsTable 1 Baseline characteristic and risk factors in AMI and
non-AMI patients.
Variable AMI patients Non-AMI
patients
p-Value
Age 56.88  10.98 53.27  10.61 0.074
Body mass index
(kg BW2)
23.42  3.41 25.7  3.22 0.000*
Total cholesterol
(mg/dl)
184.05  48.78 200.43  40.51 0.059
HDL-C (mg/dl) 38.86  11.29 44.23  10.82 0.010*
LDL-C (mg/dl) 121.28  41.27 123.72  25.31 0.664
Triglycerides
(mg/dl)
124.78  68.11 174.6  148.82 0.009*
Smoking habit (%) 0.000
Yes 90 (81.8) 20 (50)
No 20 (18.2) 20 (50)
Dyslipidemia (%) 0.000
Yes 22 (19.8) 24 (60.0)
No 89 (80.2) 16 (40.0)
Hypertension (%) 0.000
Yes 57 (51.4) 35 (87.5)
No 54 (48.6) 5 (12.5)
Family history (%) 0.053
Yes 19 (17.1) 2 (5.0)
No 92 (82.9) 38 (95.0)
* shows the significance value.having hypertension and metabolic syndrome, whereas
education and previous medication caused a low level of
BMI and triglycerides in AMI patients. Smoking behaviour in
AMI patients was higher than in non-AMI patients. No family
history of CAD in either AMI or non-AMI patients was found
(82.9% vs. 95.0%; pZ 0.000). Non-AMI patients had a higher
rate of hypertension history than AMI patients (87.5% vs.
51.4%; p Z 0.000).
The 279Phe variants (GT and TT genotypes) were found
in 2.7% of AMI patients and 7.5% of non-AMI patients. These
data were correlated with a study in Korea by Jang et al
that showed GT in 17.7% and TT in 1.3% (p Z 0.005) of AMI
patients, while 25.7% of non-AMI patients were found to
have the GT genotype and 1.2% the TT genotype.14 Also,
another study in Korea showed GT/TT genotype frequency
was lower in AMI compared to non-AMI patients.13,16,17,20
The OR of GG to GT and TT was 2.9 (95% CI 0.564e15),
showing that the GG genotype has a 2.9 times higher AMI
risk factor than the GT and TT genotypes. This condition
was supported by the Jang study in Korea, which stated
that genotype variants of GT and TT had an OR of 0.646
(95% CI 0.490e0.850). The OR of GT to GG was 0.71 (95% CI
0.53e0.95) while the OR of TT to GG was 0.6 (95% CI
0.22e1.6).16 These facts supported that Lp-PLA2 plays a
role as a proatherogenic, and an early study on a population
with intermediate risk factor is suggested because it
probably has the GG genotype. This is in accordance with
yamada and Ichihara’s study which stated that the GG ge-
notype was related to increasing Lp-PLA2 activity in a
Japanese population.20,21
Lp-PLA2 activity is high in rupture-prone plaques that
have a significant role in the formation and progressivity of
atherosclerosis in coronary events. Lp-PLA2 in atheroscle-
rotic plaques causes oxidized LDL to be hydrolysed into
lysoPC and oxidized non-esterified fatty acids (oxNEFA)
which leads to the migration of leukocytes, inflammation
cytokines, amplification of oxidation, and matrix metal-
loproteinase expression in the lesion area. This condition is
caused by the expansion of the necrotic core and attenu-
ated plaque fibrous cap that makes it easier to be ruptured.
Lp-PLa2 activity could be used to evaluate cardiovascular
risk in the future. On the other hand, inhibition of Lp-PLA2
activity will reduce the volume of the necrotic core and the
amount of macrophages, and foam cells that cause the
atherosclerosis process are inhibited. This condition is
related to the theory that missense mutation acts as an
antiatherogenic by reducing the activity of Lp-PLA2.
12,16,22
Yamada’s study in Japan also supported our findings. The
G allele is an independent risk factor in CHD of Japanese
men, but it did not have a correlation in women.20 Ac-
cording to Lee et al, the difference between the GG, GT,
and TT genotypes in every district and population was
influenced by race; the highest activity of Lp-PLA2 wasTable 2 Genotype distribution in AMI and non-AMI
patients.
Genotype AMI (n Z 111) Non-AMI (n Z 40) p
GG (%) 108 (97.3) 37 (92.5) 0.191
GT/TT (%) 3 (2.7) 3 (7.5)
Figure 1 The RFLP genotyping of Lp-PLA2. Substitution of
guanine (G) for thymine (T) at position 994 leads to the alter-
ation of amino acid from valine into phenylalanine on residue
279 (Val279Phe) of Lp-PLA2 could be used to determine the
genotype using RFLP metode. The one band for TT, two bands
for GG and Three bands for GT genotype. M is DNA marker, 1e5
were DNA samples.
Table 3 Odds ratio of GG to GT/TT in AMI and non-AMI
patients.
AMI Non AMI
GG 108 37
GT/TT 3 3
Odds ratio 2.9
292 M. Cahyaningtias et al.found in white people and intermediate activity was found
in Hispanic and African-American populations, while the
lowest activity was in the Asian population.23
According to the American College of Cardiology Foun-
dation (ACCF) and American Heart Association (AHA)
guidelines for assessment of cardiovascular risk in asymp-
tomatic adults, Lp-PLA2 might be reasonable for use in
measuring cardiovascular disease risk in asymptomatic
adult patients that have intermediate risk (IIb class, level of
evidence B). Lp-PLA2 is a biomarker that can describe its
relation to lipoprotein metabolism, vascular inflammation,
and plaque rupture.24,25 Therefore, the Val279Phe variation
of Lp-PLA2 could be used for early detection or prediction
of AMI risk in intermediate or high cardiovascular risk
patients.
Conclusion
The dominant genotype found in AMI patients was GG. The
GG genotype had a 2.9 times greater risk of AMI compared
to the GT/TT genotype. This result supported the concept
of the Val279Phe genetic variant as a proatherogenic,
which is a warrant for further development of early
detection and improving strategy to prevent AMI in
patients.Competing interests
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